Search Results

The 18th National Symposium on Radiopharmaceuticals and Labeled Compounds Held in Chongqing, Focusing on Alpha Nuclide Targeting and Theranostics

The 18th National Symposium on Radiopharmaceuticals and Labeled Compounds was held on October 10-11 at the Chongqing Science Hall. The conference was co-hosted by the China Isotope & Radiation Corporation Research Institute and the IAEA Collaborating Centre for Radiopharmaceuticals and Radioactive Sources, co-organized by the Nuclear Medicine Branch of the Chinese Medical Association, the Isotope Branch of the Chinese Nuclear Society, the Radiopharmaceuticals Branch of the Chinese Nuclear Society, and the Nuclear Chemistry and Radiochemistry Branch of the Chinese Nuclear Society, and undertaken by China Isotope & Radiation Corporation and the Chongqing Nuclear Society. More than 400 experts, scholars, clinicians and...

2026-10-12

CNNC Headway's Self-Developed 50mg Urea [¹³C] Powder Sachet Kit Approved, Establishing an Independent "Dual Dosage Form, Dual Specification" Landscape for Carbon-13 Breath Diagnosis

On October 8, 2026, the 50mg urea [¹³C] powder sachet breath test kit independently developed by Shenzhen CNNC Headway Biotechnology Co., Ltd. (CNNC Headway), a subsidiary of China Isotope & Radiation Corporation under CNNC, officially obtained the drug registration certificate issued by the National Medical Products Administration. This product is not only the first generic drug of the same variety approved for marketing in China in the 9 years since the implementation of the new drug review and approval regulations in 2017, but also another key achievement of CNNC Headway following the 75mg urea [¹³C] breath test kit becoming the first to pass the generic drug consistency evaluation, marking that China has officially formed a capsule + powder dual dosage form and 75mg + 50mg dual specification independent supply matrix in the field of Helicobacter pylori (Hp) breath testing...

2026-10-11

Radiology Institute Joins Hands with Peking Union Medical College Hospital and Tianyi Keyuan to Win Gold at National Invention Exhibition: Novel Medical Radiation Protection Materials Achieve Scaled Translational Application

At the recently held 30th National Invention Exhibition · Belt and Road & BRICS Skills Development and Technology Innovation Competition, the project "Key Technologies for Brachytherapy Radiation Protection Materials and Series of Radiation Protection Products," jointly applied for by the Institute of Radiation Medicine, Chinese Academy of Medical Sciences (Radiology Institute), Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (Peking Union Medical College Hospital), and Tianjin Tianyi Keyuan Technology Co., Ltd. (Tianyi Keyuan), stood out from numerous competing projects and won the Gold Award by virtue of key technological breakthroughs in the field of medical radiation protection. The award-winning project focuses on the long-standing radiation protection pain points in the clinical frontline of interventional therapy and brachytherapy. Through cross-disciplinary collaborative research by the three parties of medicine, research, and enterprise, it has systematically developed a series of innovative product matrices covering scenarios such as occupational health protection for medical staff, protection of normal tissues during radiotherapy for tumor patients, and specialized protection for scar radiotherapy.

2026-10-09

Civil Construction of Huizhou Heavy Ion Medical Center Passes Completion Acceptance and Transitions to Accelerator No-Load Commissioning

Recently, according to public information from the Huizhou Municipal Health Bureau, all approval procedures for the Heavy Ion Medical Center project of Huizhou Municipal Central Hospital have been completed, civil construction is 99.6% complete and has passed completion acceptance, and internal decoration and accelerator no-load commissioning are currently underway; the accelerator equipment investment is 480 million yuan, of which 303 million yuan has been disbursed. The project is planned to launch clinical trials in March 2027 and be officially put into operation by the end of the year. The center is adjacent to the Jinshan Campus of Huizhou Municipal Central Hospital, with a land area of approximately 12,000 square meters and a total floor area of 15,450 square meters; all heavy ion treatment rooms are located underground; 150 supporting inpatient beds are planned, with 2 treatment rooms to be opened initially, capable of treating approximately 900 cancer patients per year. The center...

2026-09-30

Rosatom RDS presented domestic high-end medical equipment in Perm to accelerate regional healthcare import substitution

On September 25, 2026, the Second International Conference "Bioethics – A Panoramic View of the Future" (Биоэтика – панорамный взгляд в будущее) successfully concluded in Perm, Russia. Rosatom RDS JSC (АО «Росатом РДС»), the industry integration platform under the Russian State Atomic Energy Corporation (Rosatom) responsible for instruments and electronic equipment manufacturing, participated deeply in this event. During the special seminar on "Ethical Considerations of the Peaceful Use of Atomic Energy in Medicine" held as part of the conference, Rosatom RDS representatives...

2026-09-27

Institute of Radiation Medicine, Chinese Academy of Medical Sciences Promotes the Translation and Application of Medical X-ray Skin Protective Agent

On September 10, Zhang Jianhong, Party Secretary of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, led a delegation to Nanjing to conduct research with the Institute of Dermatology, Chinese Academy of Medical Sciences and Jiangsu Haizhi Biomedical Co., Ltd., exchanging views on the translation and application of the medical X-ray skin protective agent project. Representatives from the hospital, research institute, and enterprise held discussions on industry-university-research collaboration, clinical demand alignment, and industrialization pathways. It is understood that the medical X-ray skin protective agent is one of the core products in the radiation protection series independently developed by the Institute of Radiation Medicine. After being put into production, the product is expected to become China's first medical X-ray skin protective agent for scar radiotherapy. At the symposium, Zhang Jianhong stated that dermatology...

2026-09-12

Denmark's Region East Denmark to expand Sectra One imaging platform, unifying regional nuclear medicine and other medical imaging services

Swedish medical imaging IT and cybersecurity company Sectra has recently signed a contract to expand the application of its Sectra One enterprise imaging solution from hospitals in Denmark's Capital Region to the entire Region East Denmark. Region East Denmark was formed by merging the Capital Region and Region Zealand, and this expansion aims to promote unified operation of imaging services across hospitals in the entire region. Under the contract, Sectra One will be delivered as a fully managed cloud service, covering all hospitals in Region East Denmark for the review and storage of radiology medical images, including breast imaging, nuclear medicine, and clinical physiology. Hospitals in Region Zealand will migrate to the system currently in use in the Capital Region,...

2026-09-11

Canada Supports IAEA "Rays of Hope" Initiative for the First Time, Will Provide Medical Isotope Training for Latin America

The Canadian Nuclear Isotope Council (CNIC) announced on September 10 that Canada has for the first time formally provided support to the International Atomic Energy Agency (IAEA) Rays of Hope initiative, and will help enhance cancer diagnosis and treatment capacity in Latin America through training in the production of medical radioisotopes and radiopharmaceuticals. The Rays of Hope initiative aims to expand access to cancer treatment and radiotherapy infrastructure in low- and middle-income countries. Under the arrangement, from November 8 to 14, 26 relevant sector leaders from Argentina, Brazil, Chile and Mexico will travel to Ontario, Canada, to participate in a training program jointly organized by Bruce Power and McMaster University. The training will focus on medical isotopes...

2026-09-11

US Study Says Third Course of Radiation Therapy May Improve Survival and Symptoms in Children with Recurrent DIPG

According to news from the Icahn School of Medicine at Mount Sinai in the United States on September 2, researchers at the institution released a new study on re-irradiation for recurrent diffuse intrinsic pontine glioma (DIPG). The study shows that carefully selected pediatric patients who receive a third course of radiation therapy after disease recurrence may achieve symptom relief, improved quality of life, and potentially prolonged survival. The related study has been published in Practical Radiation Oncology. DIPG is a highly aggressive pediatric brain tumor that occurs in the brainstem region. The brainstem controls critical life functions such as breathing and movement, so the tumor usually cannot be removed surgically. Data show that DIPG mainly affects children aged 5 to 10, and even...

2026-09-10

India's Fortis Healthcare Plans to Introduce the Country's First Upright Proton Therapy System

India's Fortis Healthcare has announced plans to install Mevion Medical Systems' MEVION S250-FIT proton therapy system at Fortis Memorial Research Institute (FMRI) in Gurugram. The hospital is Fortis' flagship quaternary care hospital and its comprehensive oncology and precision cancer treatment center. According to reports, the system will be equipped with Leo Cancer Care's Marie® upright patient positioning and imaging solution, as well as RaySearch Laboratories' RayStation® treatment planning software. If the project receives relevant regulatory approvals and completes site preparation, Fortis will become India's first planned...

2026-09-10

Domestically Developed "Boron Neutron Capture Therapy System" Enters the National Special Review Procedure for Innovative Medical Devices

Recently, the Medical Device Technical Review Center of the National Medical Products Administration issued a public notice on the review results of applications for the Special Review Procedure for Innovative Medical Devices (No. 14 of 2026). The boron neutron capture therapy system independently developed by Huapeng Neutron Technology (Hangzhou) Co., Ltd. has officially entered the National Special Review Procedure for Innovative Medical Devices after the public notice period. Screenshot from the official website of the Medical Device Technical Review Center of the National Medical Products Administration. The Special Review Procedure for Innovative Medical Devices is a review channel established by the National Medical Products Administration to encourage medical device innovation and promote the application of new technologies, effective since December 1, 2018. According to the relevant procedures, drug regulatory authorities and technical institutions will, on the premise of not lowering standards and not reducing procedures,...

2026-09-10

Penza State University in Russia Develops Training Simulator for X-ray Image Defect Recognition

Researchers at Penza State University in Russia have developed an interactive training simulator for identifying defects in X-ray images, aimed at helping medical students and residents more accurately assess abnormalities in medical images and understand the physical causes behind different image defects. X-ray image quality directly affects the efficiency of pathological change detection and clinical diagnostic judgment. Factors such as equipment condition, exposure parameters, radiation dose, and quantum noise levels can all lead to degraded image quality. Therefore, radiologic technologists and radiologists need not only to identify lesions in images, but also to assess image quality and determine whether defects such as low contrast, noise, blur, and artifacts may affect diagnosis...

2026-09-09

U.S. Research Team Discovers Strong Ultrafast Optical Response Induced by Ionizing Radiation, Potentially Advancing Medical Imaging and Sensing Technologies

September 3 news, Stanford University and the U.S. Department of Energy's SLAC National Accelerator Laboratory research team used ultrafast electron and laser pulses to observe a strong ultrafast optical response triggered by ionization processes in semiconductor materials. The related research has been published in Nature Photonics. The researchers believe this discovery could provide new insights for radiography and sensing technologies, and also offer experimental evidence for understanding the fundamental behavior of materials under high-energy particle interactions. Radiation detection is a key technology in particle accelerators, scientific instruments, medical imaging, and security screening equipment. Existing detectors typically face a trade-off between signal strength and response speed: processes with stronger signals tend to be slower, while those with faster response may produce weaker signals...

2026-09-08

Argentina Plans to Commission RA-10 Multipurpose Reactor in 2027

Argentina's National Atomic Energy Commission (CNEA) and the Nuclear Affairs Secretariat recently stated that the RA-10 multipurpose research reactor at the Ezeiza Atomic Centre is planned to begin commissioning before the end of this year, with the goal of achieving operation in 2027. (Image source: CNEA) According to the project site, RA-10 is currently in its final phase, with approximately 530 workers completing the remaining construction and system testing in preparation for subsequent reactor commissioning and operation. The project is currently about 96% complete overall. RA-10 is a 30 MW open-pool multipurpose research reactor that will provide products and services to the medical, scientific, technological, and industrial sectors once completed. Among these, molybdenum-99 will be one of its key products...

2026-09-08

Baiyunshan Xike Visits Jiujiang, Jiangxi to Explore Nuclear Medicine Industry Chain Cooperation

Recently, a delegation from Guangzhou Baiyunshan Xike Health Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited (GP Corp.), visited Jiujiang City, Jiangxi Province, conducting field inspections and discussion exchanges in Ruichang City, Jiujiang Economic Development Zone, and Pengze County, focusing on cooperation across the full nuclear medicine industry chain. Liu Hong, Director of the Scientific Research Project Management Department of GP Corp. and Chairman and General Manager of Baiyunshan Xike, led the core team in exchanges with Chen Shuilian, Member of the Party Leadership Group and Vice Mayor of Jiujiang Municipal People's Government, as well as responsible officials from Ruichang City, Pengze County, and Jiujiang Economic Development Zone, reaching multiple consensuses on subsequent cooperation. The inspection covered key facilities including the Ruichang Institute of Nuclear Physics Applications, the Biomedical (Nuclear) Industrial Park in Jiujiang Economic Development Zone, and the Jiangxi Tianhong Nuclear Technology project site in Pengze County. The delegation conducted in-depth visits to research laboratories, industrial parks, and projects under construction to understand local capabilities in nuclear technology research, isotope R&D infrastructure, project construction progress, as well as land and industrial supporting conditions.

2026-09-07